By ThinkSabio #ThinkSabio Latest News
BioNTech to Acquire Biotheus to Boost Oncology Strategy
BioNTech announces the acquisition of Biotheus for $800 million upfront plus up to $150 million in milestone payments. The deal includes full global rights to BNT327/PM8002, a late-stage bispecific antibody targeting PD-L1 and VEGF-A for cancer treatment.